Skip to main content
SpringerLink
Log in

Properties of labetalol, a combined α-and β-blocking agent, relevant to the treatment of myocardial ischemia

  • Symposium on Combined Alpha- and Beta Blockade in Angina
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Labetalol, a combined α-β-adrenergic antagonist, is one of the new group of β-adrenergic blockers reduces peripheral and coronary vascular resistances while preserving cardiac output. Unlike α-adrenergic blockers, labetalol tends to reduce heart rate during rest and exercise. The drug is a potent antihypertensive agent which has been used by mouth and by vein to treat mild, moderate, and severe hypertension, including hypertensive emergencies. Labetalol has a hemodynamic profile which makes it an attractive agent for treating myocardial ischemia. The drug reduces blood pressure, left ventricular wall tension, heart rate, and contractility while preserving or even augmenting coronary blood flow. Studies with labetalol in hypertensive patients with angina have shown it to be more effective than placebo in reducing angina attacks and blood pressure while improving exercise tolerance. The drug appears to have antianginal and antihypertensive effects comparable to atenolol and propranolol. Side effects of treatment are observed and most are related to α- and β-adrenergic blockade. Labetalol also appears to be effective for treatment of normotensive patients with angina and for silent myocardial ischemia. It has no apparent effects on serum lipids and lipoproteins. Labetalol appears to be a useful drug for treating the hypertensive heart and its many complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: Labetalol. Am Heart J 1979; 98:660–665.

    Google Scholar 

  2. Farmer JB, Kennedy I, Levy GP, Marshall RJ: Pharmacology of AH5158: A drug which blocks both α- and β-adrenoceptor blocking drugs. Br J Clin Pharmacol 1972; 45:660–675.

    Google Scholar 

  3. Wallin JD, O'Neill WM: Labetalol. Arch Intern Med 1983; 143:485–490.

    Google Scholar 

  4. Frishman WH, Strom JA, Kirschner M, et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: Effects of combined alpha and beta-adrenoceptor blockade. Am J Cardiol 1981; 48:917–927.

    Google Scholar 

  5. MacCarthy EP, Bloomfield SS. Labetalol: A review of ita pharmacology, pharmacokinetic elinical uses and side effects. Pharmacotherapy 1983; 3:193–219.

    Google Scholar 

  6. Brittain RT, Drew GM, Levy GP. The α- and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anesthetized dogs and in isolated tissues. Br J Pharmacol 1982; 77:105–114.

    Google Scholar 

  7. Aggerbeck M, Guellaen G, Hanoune J. N-alkyl substitution increases the affinity of adrenergic drugs for the α-adrenoceptor in rat liver. Br J Pharmacol 1979; 65:15–22.

    Google Scholar 

  8. Brittain RT, Levy GP. A review of the animal pharmacology of labetalol, a combined α- and β-adrenoceptor blocking drug. Br J Clin Pharmacol 1976; 3 (Suppl 3):681–694.

    Google Scholar 

  9. Blakeley AG, Summers RJ. The pharmacology of labetalol, an α- and β-adrenoceptor blocking agent. Gen Pharmacol 1978; 9:399–402.

    Google Scholar 

  10. Baum T, Sybertz EJ. Pharmacology of labetalol in experimental animals. Am J Med 1983; 75 (4A):15.

    Google Scholar 

  11. Carey B, Whalley ET. Labetalol possesses β-adrenoceptor agonist action on the isolated rat uterus. J Pharm Pharmacol 1979; 31:791–792.

    Google Scholar 

  12. Carey B, Whalley ET. β-adrenoceptor agonist activity of labetalol on the isolated rat uterus. Br J Pharmacol 1979; 67:13–15.

    Google Scholar 

  13. Carpenter JR. Intrinsic activity of labetalol on guinea pig isolated trachea. J Pharm Pharmacol 1981; 33:806–807.

    Google Scholar 

  14. Johnson GL, Prioli NA, Ehrreich SJ. Antihypertensive effects of labetalol (SCH 15719W, AH5158A) (abstr). Fed Proc 1977; 36:1049–1053.

    Google Scholar 

  15. Dage RC, Hsieh CP. Direct vasodilatation by labetalol in anesthetized dogs. Br J Pharmacol 1980; 70:287–293.

    Google Scholar 

  16. Sybertz EJ, Sabin CS, Pula KK, et al. Alpha and beta-adrenoceptor blocking properties of labetalol and its R-R-isomer, SCH 19927. J Pharmacol Exp Ther 1981; 218:435–442.

    Google Scholar 

  17. Katano Y, Takeda K, Nakagawa Y, et al. α- and β-adrenoceptor blocking actions of labetalol and effects on the myocardial function, coronary circulation and myocardial energy metabolism thereof. Folia Pharmacol Jpn 1978; 74:819–832.

    Google Scholar 

  18. Blakeley AG, Summars RJ. The effects of labetalol (AH5158) on adrenergic transmission in the cat spleen. Br J Pharmacol 1977; 59:643–650.

    Google Scholar 

  19. Levy GP, Richards DA. Labetalol In: Scriabine A, ed. Pharmacology of Antihypertensive Agents. New York: Raven Press, 1980; 325–347.

    Google Scholar 

  20. Hoffman BB, Lefkowitz R. Alpha-adrenergic receptor subtypes. N Engl J Med 1982; 302:1390–1397.

    Google Scholar 

  21. Boakes AJ, Knight EJ, Prichard BNC. Preliminary studies of the pharmacologic effects of 5–1-hydroxy-2-(1-methyl-3 phenylpropyl) amino ethyl salicyolamide (AH 5158) in man. Clin Sci 1971; 40:188–192.

    Google Scholar 

  22. Richards DA. Pharmacologic effects of labetalol in man. Br J Clin Pharmacol 1976; 3(Suppl 3):721–773.

    Google Scholar 

  23. Richards DA, Prichard BNC, Dobbs RJ. Adrenoceptor blockade of the circulatory responses to intravenous isoproterenol. Clin Pharmacol Ther 1978; 24:264–273.

    Google Scholar 

  24. Richards DA, Woodings EP, Stephen MDB, et al. The effects of oral AH5158, a combined α- and β-adrenoceptor antagonist in healthy volunteers. Br J Clin Pharmacol 1974; 1:505–509.

    Google Scholar 

  25. Richards DA, Prichard BNC, Boakes AJ, et al. Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J 1977; 39:99–106.

    Google Scholar 

  26. Richards DA, Prichard BNC, Hernandez R. Circulatory effects of noreadrenaline and adrenaline befor and after labetalol. Br J Clin Pharmacol 1979; 7:371–378.

    Google Scholar 

  27. Richards DA, Tuckman J, Prichard BNC. Assessment of alpha and beta-adrenoceptor blocking action of labetalol. Br J Clin Pharmacol 1976; 3:849–855.

    Google Scholar 

  28. Maconochie JG, Richards DA, Woodings EP. Modification of pressor responses induced by “cold” (abstr). Br J Clin Pharmacol 1977; 4:389–394P.

    Google Scholar 

  29. Richards DA, Maconochie JG, Bland RE, et al. Relationship between plasma concentrations and pharmacological effects of labetalol. Eur J Clin Pharmacol 1977; 11:85–90.

    Google Scholar 

  30. Mehta J, Cohn JN. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation 1977; 55:370–375.

    Google Scholar 

  31. Baum T, Watkins B, Sybertz Z, et al. Antihypertensive and hemodynamic actions of SCH 19927, the R-R isomer of labetalol. J Pharmacol Exp Ther 1981; 218:444–457.

    Google Scholar 

  32. Majid PA, Meeran MK, Benaim ME, et al. α- and β-Adrenoceptor blockade in the treatment of hypertension. Br Heart J 1974; 36:588–594.

    Google Scholar 

  33. Maxwell GM. The effects of a new alpha and beta-adrenoceptor antagonist (AH 51581) upon the general and coronary hemodynamics of intact dogs. Br J Clin Pharmacol 1973; 49:370–372.

    Google Scholar 

  34. Chen DG, Dai X-Z, Zimmerman BG, Bache RJ. Postsynaptic α1-and β2-adrenergic mechanisms in coronary vasoconstriction. J Cardiovasc Pharmacol 1988; 11:61–68.

    Google Scholar 

  35. Brittain RT, Harris DM, Jack D, et al. Labetalol. In: Goldberg ME, ed. Pharmacological and biochemical properties of drug substances. Am Pharm Assoc Acad Pharm Sci 1979:229–254.

  36. Drew GM, Hilditch A, Levy GP. The relationships between the cardiovascular effects, α- and β-adrenoceptor blocking actions and plasma concentration of labetalol in DOCA hypertensive rats. Clin Exp Hypertens 1979; 1:597–611.

    Google Scholar 

  37. Koch G. Hemodynamic changes after acute and long-term combined alpha-beta adrenoceptor blockade with labetalol as compared with beta-receptor blockade. J Cardiovasc Pharmacol 1981; 3(Suppl 1):s30-s41.

    Google Scholar 

  38. Agabiti-Rosei E, Alicandri CL, Beschi M, et al. The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels. Br J Clin Pharmacol 1982; 13 (Suppl 1):87s-96s.

    Google Scholar 

  39. Joekes AM, Thompson FD. Acute haemodynamic effects of labetalol and its subsequent use as an oral hypotensive agent. Br J Clin Pharmacol 1976; 3(Suppl 3):789–793.

    Google Scholar 

  40. Koch G. Cardiovascular dynamics after acute and long-term α- and β-adrenoceptor blockade at rest, supine and standing, and during exercise. Br J Clin Pharmacol 1979; 8 (Suppl 2):101s-107s.

    Google Scholar 

  41. Svendsen TL, Rasmussen S, Hartling OJ. Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension. Postgrad Med J 1980; 56 (Suppl 2):21–26.

    Google Scholar 

  42. Prichard BNC, Thompson FO, Boakes AJ, et al. Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydralazine, and diazoxide: The use of AH 5158 in the treatment of hypertension. Clin Sci Mol Med 1975; 48:97s-102s.

    Google Scholar 

  43. Bahlmann J, Brod J, Hubrich W, et al. Effect of an α- and β-adrenoceptor blocking agent (labetalol) on haemodynamics in hypertension. Br J Clin Pharmacol 1979; 8(Suppl 2):113s-116s.

    Google Scholar 

  44. Trap-Jensen J, Clausen JP, Hartling OJ, et al. Immediate effects of labetalol on central, splanchnic-hepatic, and forearm haemodynamics during pleasant emotional stress in hypertensive patients. Postgrad Med J 1980; 56(Suppl 2):37–46.

    Google Scholar 

  45. Omvik P, Lund-Johansen P. Acute hemodynamic effects of labetalol in severe hypertension. J Cardiovasc Pharmacol 1982; 4:915–919.

    Google Scholar 

  46. Lund-Johansen P. Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br J Clin Pharmacol 1979; 8(Suppl 2):107s-114s.

    Google Scholar 

  47. Edwards RC, Raftery EB. Haemodynamic effects of long-term oral labetalol. Br J Clin Pharmacol 1976; 3(Suppl 3):733–740.

    Google Scholar 

  48. Fagard R, Amery A, Reybrouck T, et al. Response of the systemic and pulmonary circulation to alpha and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients. Circulation 1979; 60:1214–1219.

    Google Scholar 

  49. Lund-Johansen P. Acute and chronic (six years) hemodynamic effects of labetalol in essential hypertension. Am J Med 1983; 75(4A) (Suppl):24–30.

    Google Scholar 

  50. Gagnon RM, Morissette M, Presant S, et al. Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease. Am J Cardiol 1982; 49:1267–1271.

    Google Scholar 

  51. Prida XE, Hill JA, Feldman RL. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 1987; 59:1084–1088.

    Google Scholar 

  52. Feldman RL, Prida XE, Lambert CR, Hill JA. Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease. Cardiovasc Drugs Ther (in press).

  53. Breckenridge A, Orme M, Serlin MJ, Maciver M. Labetalol in essential hypertension. Br J Pharmacol 1982; 13 (Suppl 1):37s-41s.

    Google Scholar 

  54. Brogden RN, Heel RC, Speight TM, Avery GS. Labetalol: A review of its pharmacology and therapeutic uses in hypertension. Drugs 1978; 15:251–270.

    Google Scholar 

  55. Prichard BNC, Richards DA. Comparison of labetalol with other antihypertensive drugs Br J Clin Pharmacol 1982; 13 (Suppl 1):41s-45s.

    Google Scholar 

  56. Kane JA. Labetalol in general practice. Br J Clin Pharmacol 1982; 13(Suppl 1):59s-62s.

    Google Scholar 

  57. Dargie HJ, Dollery CT, Daniel J. Labetalol in resistant hypertension. Br J Clin Pharmacol 1976; 3(Suppl 3):751–755.

    Google Scholar 

  58. Milne BJ, Logan AG. Labetalol: Potent antihypertensive agent that blocks both αN and β-adrenergic receptors. Can Med Assoc J 1980; 123:1013–1020.

    Google Scholar 

  59. Frick MH, Porsti P. Combined alpha amd beta-adrenoceptor blockade with labetalol in hypertension. Br Med J 1976; 1:1046–1053.

    Google Scholar 

  60. Larochelle P, Hamet P, Hoffman B, et al. LLabetalol in essential hypertension. J Cardiovasc Pharmaco 1980; 2:751–755.

    Google Scholar 

  61. Davidov ME, Moir GD, Poland MP, et al. Monotherapy with labetalol in the treatment of hypertension. A double-blind study. Am J Med 1983; 75(4A) (Suppl):47–53.

    Google Scholar 

  62. Kane J, Gregg I, Richards DA. A double-blind trial of labetalol. Br J Clin Pharmacol 1976; 3(Suppl 3):737–744.

    Google Scholar 

  63. Dawson A, Johnson BF, Smith IK. Comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol 1979; 8:149–154.

    Google Scholar 

  64. Horvath JS, Caterson RJ, Collett P, et al. Labetalol and bendrofluazide: Comparison of their antihypertensive effects. Med J Aust 1979; 1:626–632.

    Google Scholar 

  65. Lifshitz AA, McMahon FG, Jain AK, et al. Combined trichlormethiazide and labetalol therapy in moderate to severe hypertension (abstr). Clin Pharmacol Ther 1978; 23:118–122.

    Google Scholar 

  66. Bloomfield S, Sinkfield A, Bichlmeir G, et al. Labetalol with hydrochlorothiazide for moderate essential hypertension (abstr). Clin Pharmacol Ther 1982; 31:204–208.

    Google Scholar 

  67. Lechi A, Pomari S, Berto R, et al. Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: A double-blind multicentre controlled study. Eur J Clin Pharmacol 1982; 22:289–294.

    Google Scholar 

  68. Bloomfield SS, Lucas CP, Gantt CL, et al. Step II treatment with labetalol for essential hypertension. Am J Med 1983; 75(4A) (Suppl):81–89.

    Google Scholar 

  69. Michelson EL, Frishman WH, Lewis JE et al. Multicenter clinical evaluation of the long-term efficacy and safety of labetalol in the treatment of hypertension. Am J Med 1983; 75(4A) (Suppl):68–80.

    Google Scholar 

  70. Hunyor SN, Bauer GE, Ross M, Larkin H. Labetalol and propranolol in mild hypertensives: Comparison of blood pressure and plasma volume effects. Aust NZ J Med 1980; 10:162–166.

    Google Scholar 

  71. Prichard BNC, Boakes AJ. Labetalol in long-term treatment of hypertension. Br J Clin Pharmacol 1980; 3 (Suppl 3):743–749.

    Google Scholar 

  72. McNeil JJ, Louis WJ. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol 1979; 8 (Suppl 2):163s-166s.

    Google Scholar 

  73. Romo M, Halttunen P, Saarinen P, Sarna S. Labetalol and pindolol in the treatment of hypertension: A comparative study. Ann Clin Res 1979; 11:249–252.

    Google Scholar 

  74. Pugsley DJ, Nassim M, Armstrong BK, Bellin L. A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension. Br J Clin Pharmacol 1979; 7:63–68.

    Google Scholar 

  75. Kofod P, Kjaer K, Vejlo S, Hvidt S. Labetalol and alprenolol: A comparative investigation of antihypertensive effect. Postgrad Med J 1980; 56 (Suppl 2):69–74.

    Google Scholar 

  76. Bjerle P, Fransson L, Koch G, et al. Pindolol and labetalol in hypertension: Comparison of their antihypertensive effects with particular respect to conditions in the upright posture and during exercise. Curr Ther Res 1980; 27:516–523.

    Google Scholar 

  77. Pugsley DJ, Armstrong BK, Nassim MA, et al. Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br J Clin Pharmacol 1976; 3 (Suppl 3):777–782.

    Google Scholar 

  78. Nicholls DP, Husaini MH, Bulpitt CJ, et al. Comparison of labetalol and propranolol in hypertension. Br J Clin Pharmacol 1980; 9:233–238.

    Google Scholar 

  79. Saunders E, Curry C, Hinds J, et al. Labetalol compared to propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987; 3:294–337.

    Google Scholar 

  80. Ghose RR, Sampson A. Rapid onset of action of oral labetalol in severe hypertension. Curr Med Res Opin 1977; 5:147–151.

    Google Scholar 

  81. Davies AB, Bala Subramanian V, Gould B, Raftery EB. Rapid reduction of blood pressure with acute oral labetalol. Br J Clin Pharmacol 1982; 13:705–711.

    Google Scholar 

  82. Pearson RM, Griffith DNW, Woollard M, et al. Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: Preliminary findings. Br J Clin Pharmacol 1979; 8 (Suppl 2):195s-198s.

    Google Scholar 

  83. Wilson DJ, Wallin JD, Vlachakis ND, et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med 1983; 75 (4A) (Suppl):95–102.

    Google Scholar 

  84. Frishman WH, Strom JA, Kirschner M, et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: Effects of combined alpha and beta adrenoceptor blockade. Am J Cardiol 1981; 48:917–928.

    Google Scholar 

  85. Frishman W, Charlap S, Kimmel B, et al. Comparison of labetalol to propranolol in patients with both angina pectoris and hypertension: A double-blind study (abstr). J Am Coll Cardiol 1986; 7:27a.

  86. Opie LH. Role of vasodilation in the antihypertensive and antianginal effects of labetalol. Implications for therapy of combined hypertension and angina. Cardiovasc Drugs Ther (in press).

  87. Fox K, Guyyumi AA. Labetalol in normotensive patients with angina pectoris. Cardiovasc Drugs Ther (in press).

  88. Rocco MB, Nobel E, Mead K, et al. Effects of beta vs alpha/beta blockade on transient myocardial ischemia (abstr). Circulation 1987; 76 (Suppl 4):27.

    Google Scholar 

  89. Waal-Manning HJ, Simpson FO. Review of long-term treatment of hypertension with labetalol. Br J Clin Pharmacol 1982; 13 (Suppl 1):65–73.

    Google Scholar 

  90. Takeda T, Kaneko Y, Omae T, et al. The use of labetalol in Japan: Results of multicentre clinical trials. Br J Clin Pharmacol 1982; 13 (Suppl 1):49s-57s.

    Google Scholar 

  91. Kane J, Gregg I, Richards DA. A double-blind trial of labetalol. Br J Clin Pharmacol 1976; (Suppl 3):737–741.

  92. Gange RW, Wilson Jones E. Bullous lichen planus caused by labetalol. Br Med J 1978; 1:816–817.

    Google Scholar 

  93. Finlay AY, Waddington E. Cutaneous reactions to labetalol (letter). Br Med J 1978; 1:987.

    Google Scholar 

  94. Branford WA, Hunter JAA, Muir AL. Cutaneous reaction to labetalol. Practitioner 1978; 221:765–767.

    Google Scholar 

  95. Kristensen BO. Labetalol-induced Peyronie's disease? Acta Med Scand 1979; 206:511–512.

    Google Scholar 

  96. Collier JG, Dawnay NAH, Nachev CH, et al. Clinical investigation of an antagonist at α- and β-adrenoceptors AH 5158A. Br J Pharmacol 1972; 44:286–293.

    Google Scholar 

  97. Andersson O, Berglund G, Hansson L. Antihypertensive action, time of onset and effects on carbohydrate metabolism of labetalol. Br J Clin Pharmacol 1976; 3 (Suppl 3):757–761.

    Google Scholar 

  98. Seedat YK. Labetalol in the treatment of Black and Indian hypertensive patients. Med Proc 1979; 25:53.

    Google Scholar 

  99. Griffiths ID, Richardson J. Lupus-type illness associated with labetelol. Br Med J 1979; 2:496–497.

    Google Scholar 

  100. Stevenson CJ. Antimitochondrial antibodies associated with labetalol (letter). Lancet 1980; 2:924.

    Google Scholar 

  101. Wilson JD, Booth RJ, Bullock JY, Campbell DG. Antimitochondrial antibodies associated with labetalol. Lancet 1980; 2:312–313.

    Google Scholar 

  102. Hachamovitch R, Sonnenblick EH, Strom JA, Frishman WH. Left ventricular hypertrophy in hypertension and the effects of antihypertensive drug therapy. Curr Prob Cardiol 1988; 13:371–421.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Albert Einstein College of Medicine, Bronx, New York

    William H. Frishman

Authors
  1. William H. Frishman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frishman, W.H. Properties of labetalol, a combined α-and β-blocking agent, relevant to the treatment of myocardial ischemia. Cardiovasc Drug Ther 2, 343–353 (1988). https://doi.org/10.1007/BF00054642

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054642

Key words

Search

Navigation